Used in immunotherapy research and development, particularly in cancer treatment and immune system modulation. This antibody targets the KIR2DL1 receptor on natural killer (NK) cells, blocking inhibitory signals that prevent NK cell activation. By inhibiting this checkpoint, the antibody enhances NK cell-mediated killing of tumor cells, especially those with low MHC class I expression. It is employed in the design of therapeutic antibodies, antibody-drug conjugates, and in combination with other immunotherapies such as monoclonal antibodies or checkpoint inhibitors to boost anti-tumor responses. Also utilized in flow cytometry and cell isolation techniques to study NK cell populations and their role in immune surveillance.

Additionally, this antibody is studied in the treatment of patients undergoing bone marrow transplantation, particularly haploidentical transplantation, to help reduce graft-versus-host disease by mitigating immune rejection against the patient's tissues and to promote NK cell responses against residual cancer cells.

The use of this antibody has potential to enhance cancer treatment efficacy, especially for leukemias and lymphomas, and is part of developing personalized approaches in oncology.